scholarly journals Home treatment and use of informal market of pharmaceutical drugs for the management of paediatric malaria in Cotonou, Benin

2018 ◽  
Vol 17 (1) ◽  
Author(s):  
Edwige Apetoh ◽  
Marina Tilly ◽  
Carine Baxerres ◽  
Jean-Yves Le Hesran
Keyword(s):  
Home Treatment ◽  
Pharmaceutical Drugs ◽  
Informal Market ◽  
Paediatric Malaria

A Multicenter Study of Recombinant Factor VIII (RecombinateTM) in Previously Treated Patients with Hemophilia A

1997 ◽  
Vol 77 (04) ◽  
pp. 660-667 ◽  
Author(s):  
G C White ◽  
S Courter ◽  
G L Bray ◽  
M Lee ◽  
E D Gomperts ◽  
...  
Keyword(s):  
Hemophilia A ◽  
Recombinant Dna ◽  
Home Treatment ◽  
Pharmacokinetic Parameters ◽  
Pharmacokinetic Studies ◽  
Open Label ◽  
Treat Ment ◽  
Previously Treated Patients ◽  
Bleeding Episodes

SummaryA prospective, open-label multicenter investigation has been conducted to compare pharmacokinetic parameters of recombinant DNA-derived FVIII (rFVIII) and plasma-derived FVIII concentrate (pdFVIII) and to assess safety and efficacy of long-term home-treat- ment with rFVIII for subjects with hemophilia A. Following comparative in vivo pharmacokinetic studies, 69 patients with severe (n = 67) or moderate (n = 2) hemophilia A commenced a program of home treatment using rFVIII exclusively for prophylaxis and treatment of all bleeding episodes for a period of 1.0 to 5.7 years (median 3.7 years). The mean in vivo half-lives of rFVIII and pdFVIII were both 14.7 h. In vivo incremental recoveries at baseline were 2.40%/IU/kg and 2.47%/IU/kg, respectively (p = 0.59). The response to home treatment with rFVIII was categorized as good or excellent in 3,195 (91.2%) of 3,481 evaluated bleeding episodes. Thirteen patients received rFVIII for prophylaxis for twenty-four surgical procedures. In all cases, hemostasis was excellent. Adverse reactions were observed in only 13 of 13,591 (0.096%) infusions of rFVIII; none was serious. No patient developed an inhibitor to r FVIII.

Problems Facing the Arab Pharmaceutical Industry: A Case Study from Yemen

2016 ◽  
Vol 2 (4) ◽  
pp. 234-241
Author(s):  
Mohammed Al-Shakka ◽  
Ebtesam Abood ◽  
Adel Al-Dhubhany ◽  
Sami Abdo Radman Aldubai ◽  
Khaled Said ◽  
...  
Keyword(s):  
Pharmaceutical Industry ◽  
Low Income ◽  
Well Being ◽  
Pharmaceutical Products ◽  
Domestic Market ◽  
Raw Material ◽  
Political Crisis ◽  
Pharmaceutical Manufacturer ◽  
University Graduates ◽  
Pharmaceutical Drugs

Because of the almost-instant connection with the welfare and well-being of individuals, pharmaceutical industry stands prominently as a very important factor for the improvement and progress of a healthy productive nation. These days, pharmaceutical industry thrives as one of the largest and exponentially expanding global industries. Nonetheless, millions of people in low income developing countries, have to suffer from the fatal consequences of the inaccessibility and non-availability of essential drugs. This is also happening in Yemen, where the pharmaceutical manufacturers sector have to face up to many challenges. The Yemen Drug Company (YEDCO) was founded in 1964 by the Yemeni government as it collaborated with private investors. It was endorsed as a company with the expertise in the medicinal drug marketing. YEDCO started its work by taking in drugs from foreign companies and then locally marketing and distributing them. In 1982, YEDCO built the first medicinal factory for drugs in Sana’a. Since then, seven companies were set up to manufacture medicines in Yemen. The expanding population has led to the need to have more pharmaceutical products. It may be understandable that pharmaceutical manufacturer companies are also hit by the political crisis in the country. Inadequate amount of fuel and raw material as well as low security status were some of the underlying factors behind these ill-effects in Yemen. Imported drugs make up about nearly 90% % of the pharmaceutical market compared to 10% drugs from the domestic market. This situation has led to an additional burden being shouldered by the national economy, where Yemen spends about US$263 million annually on pharmaceutical drugs, in reference to the national Supreme Drugs Authority. Although there is a very quick growth in the population and drugs consumption, the pharmaceutical industry has not been very active, where global pharmaceutical products play their role dominantly on the domestic market. The pharmaceutical production necessitates skilled human resources like university graduates. By contrast, the government and the private sector should also motivate the pharmaceutical industry and make use of the local employment

Clinical approbation of remote monitoring in treatment of patients in hospital and home care for patients with limited mobility

2020 ◽  
pp. 44-49
Author(s):  
A. A. Eryomenko ◽  
N. V. Rostunova ◽  
S. A. Budagyan ◽  
L. S. Sorokina
Keyword(s):  
High Risk ◽  
Home Care ◽  
Remote Monitoring ◽  
Emergency Situation ◽  
Home Treatment ◽  
Clinical Testing ◽  
Telemedicine System ◽  
Medical Supervision ◽  
Limited Mobility

The article describes the experience of clinical testing of the personal telemedicine system (PTS) ‘Obereg’ for remote monitoring of patients with the consequences of severe conditions in leading Russian clinics. It is shown that such patients are at high risk of complications when transferred from the ICU to a normal ward with limited medical supervision and lack of instrumentation. The use of remote monitoring using the personal telemedicine system ‘Obereg’ allows to solve this problem. The results of the use of PTS ‘Obereg’ for the organization of monitoring in the home patronage of patients with limited mobility are presented. It is indicated that such devices should be used in an emergency situation similar to a coronavirus pandemic to monitor patients who are in infectious boxes and on home treatment.

Vaccines for aquaculture overview

2020 ◽  
pp. 42-43
Author(s):  
Andrey S. Khishov ◽  
◽  
Galina I. Burlakova ◽  
Keyword(s):  
Antimicrobial Agents ◽  
Aquatic Organisms ◽  
Animal Husbandry ◽  
Well Being ◽  
Pharmaceutical Drugs ◽  
Short Development Time ◽  
The Creation ◽  
Basic And Applied Research ◽  
North And South America ◽  
Aquaculture Production

Aquaculture production is a promising direction for the development of food production. Like traditional types of animal husbandry, it needs effective medicines for veterinary use, which would ensure not only the well-being of farmed aquatic organisms, but also increase the safety of the fish products and non-fish objects of fishing. The development of measures to control epizootic processes in aquatic organisms is impossible without the creation of new immunological preparations. The development and use of immunobiological drugs will reduce the use of antimicrobial agents. The corresponding set of pharmaceutical drugs was transferred from the traditional veterinary medicine, but due to the peculiarities of the biology of aquatic animals, their immunity and the characteristics of specific pathogens, this could not be done with biological products. The short development time in the aquaculture industry poses current challenges in the form of a lack of basic and applied research for relatively poorly understood groups of new pathogens. The immunological processes associated with the development and intensity of the immune response in aquatic organisms require a detailed study. For domestic aquaculture producers, the analysis and dissemination of the experience accumulated by mankind and the application of advanced developments in this area are even more relevant, since Russia is just beginning its path of intensifying aquaculture production. At the same time, it is clear that the prohibition of the use and monitoring of antimicrobial agents in food products and feed requires a change in the approach to the problem and will lead to the creation of new immunobiological drugs. The market for immunobiological preparations for aquaculture is the most promising for development. In the article, the authors provide data on the development and registration of vaccines for aquaculture in Europe, North and South America.

A cost-effective preventative approach to potentially save lives in the coronavirus pandemic, jointly using Vitamin D, Curcumin, and Vitamin C. Authors Bakare T A and Soar J S

2020 ◽  
Author(s):  
Jagjit S Soar
Keyword(s):  
Vitamin D ◽  
Vitamin C ◽  
Cost Effective ◽  
Risk Groups ◽  
The Elderly ◽  
Pharmaceutical Drugs ◽  
Over The Counter ◽  
Literature Searches ◽  
Pharmaceutical Agents ◽  
And Control

he current COVID-19 pandemic now believed to be based on the mutation of the SARS-CoV virus (first reported in 2002) to SARS-CoV-2 emerging in 2019, is naturally causing extreme worry and concern around the world with sometimes mixed and incoherent messages on how to deal with it. There is a plethora of information from previous epidemics caused by other coronaviruses such as severe acute respiratory syndrome, SARS (2002) and Middle East respiratory syndrome MERS (2012) from which we can extrapolate guidance on how to deal with the current pandemic. In the current absence of specific pharmaceutical agents, we propose assessing the extended tools that we already possess in our biological armoury to combat, prevent and control the spread of this virus. Using a set of precise criteria to locate such possible contenders, we conducted literature searches to find compounds that met these criteria. We have now reduced this to a shortlist of three agents that may be the best candidates. We propose vitamin C, vitamin D and Curcumin fit our criteria well. These compounds are widely available to the general public. They are available online and over-the-counter as supplements. Otherwise healthy individuals are safely able to self-administer these agents as a prophylactic to protect themselves and to enhance their immune response. This would be especially desirable for the elderly and at risk groups. These agents can also be used as adjunct therapy, particularly for those who may have early symptoms. This preventative therapy could be implemented whilst awaiting specific pharmaceutical drugs to emerge as a treatment for COVID-19. Our suggested compounds are a highly cost-effective way to potentially reduce the mortality that is regretfully mounting as a result of COVID-19 infection. The biological mode of action and the dosing of these compounds are summarised.

Sign in / Sign up

Export Citation Format

Share Document